HistoSonics has closed a new strategic financing round that values the non-invasive cancer therapy developer at $3.75 billion, adding Yosemite and Reed Jobs among its backers. The Minneapolis-based medical device company did not disclose the size of the investment, but said the capital will help advance commercial deployment, clinical studies and regulatory work across its histotripsy platform. The funding arrives as HistoSonics expands use of its Edison Histotripsy System for liver tumors while pursuing additional applications in kidney, pancreas and other solid tumors.
Strategic Investor Support
Yosemite, a healthcare-focused investment firm led by Reed Jobs and built around a mission to make cancer non-lethal in his lifetime, joined several undisclosed strategic investors in the financing. Jobs described HistoSonics as a company advancing a new method for treating some of the world’s deadliest cancers and said Yosemite intends to support broader development of the technology. Mike Blue, HistoSonics’ chairman and chief executive, said the round adds investors with strategic alignment around the company’s goals for patients, clinicians and shareholders.
Commercial Momentum in Liver Care
HistoSonics said it has gained commercial and clinical traction over the past year as more physicians and major academic medical centers adopt histotripsy to treat liver tumors, including metastatic disease. The Edison Histotripsy System has US Food and Drug Administration De Novo clearance for the destruction of liver tumors, allowing the company to commercialize the device in the United States and selected international markets. Rising utilization within hospital systems is central to the company’s effort to establish histotripsy as a practical non-invasive option within oncology care pathways.
Broadening the Clinical Pipeline
The company has also submitted a De Novo request to the FDA seeking clearance for the destruction of kidney tumors, a potential next step in extending its platform beyond the liver. If authorized, the kidney indication could create a significant new clinical and commercial opportunity, while offering physicians another approach for targeting localized tumors without surgery or radiation. In parallel, HistoSonics is reporting encouraging early clinical experience in primary pancreatic tumors and is progressing toward an anticipated FDA submission as technical and clinical milestones are met.
How the Technology Works
Histotripsy uses focused ultrasound energy and acoustic cavitation to mechanically break down targeted tissue, with the goal of destroying and liquefying tumors without an incision or ionizing radiation. The technique differs from established approaches by using a precisely directed sonic beam rather than thermal ablation, surgical instruments or radiation delivery. While the Edison system is cleared for liver tumors, any use in other organs currently remains investigational until the relevant regulatory clearances are obtained.
Funding Priorities and Expansion Plans
HistoSonics said the new capital will be directed toward commercial expansion, ongoing clinical development, additional regulatory initiatives and further progress across its pipeline of potential applications. Beyond liver, kidney and pancreas programs, the privately held company is exploring how its proprietary platform could be applied to organs including the prostate, as it seeks to widen the addressable patient population. The company operates from offices in Ann Arbor, Madison and Minneapolis, combining commercial operations with technical and clinical development capabilities.
The financing gives HistoSonics additional strategic backing as it seeks to turn histotripsy from a liver-focused technology into a multi-organ therapeutic platform. Near-term milestones will include the FDA’s review of its kidney submission, continued growth in liver treatment adoption and progress toward a pancreatic application filing. The company’s ability to translate promising clinical experience into regulatory authorizations and routine hospital use will determine whether its $3.75 billion valuation is sustained by long-term patient and market impact.